Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

administered once every three weeks. The most common adverse events reported thus far include nausea, fatigue, vomiting and alopecia. There was a low rate of febrile neutropenia or other Grade 3/4 adverse events, and manageable Grade 1/2 nausea or vomiting.

Based on the indications of clinical activity and the acceptable tolerability profile demonstrated to date among this patient population, the dose of SNS-595 in this trial has been increased to 60 mg/m2 over twenty-eight days. Patient accrual at this dose level is ongoing.

"We are pleased by the strong signal of activity emerging from our Phase 2 clinical trial of SNS-595 at the 48mg/m2 dose level. Based on the drug's observed safety profile and recommendations from advisors, we are exploring a higher dose of SNS-595 in this trial. Enrollment has begun at 60 mg/m2 and we expect to enroll approximately 30 patients at this dose by the third quarter of this year," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Enthusiasm for SNS-595 among our clinical investigators is growing and enrollment in this trial has been accelerating. We expect to present further data from this Phase 2 clinical trial this year."

The interim clinical results are being presented in a poster, "A Phase 2 Trial of SNS-595 in Women with Platinum-Refractory Epithelial Ovarian Cancer" (Abstract # 290), at the 39th Annual Meeting on Women's Cancer hosted by the Society of Gynecologic Oncologists (SGO) in Tampa, Fla. through March 12, 2008.

About SNS-595

SNS-595 is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double strand DNA damage, irreversible G2 arrest and rapid apoptosis. In non-clinical evaluations, SNS-595 demonstrates broad and potent a
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... FRANCISCO, Nov. 8, 2011 InspireMD, Inc. (OTC ... device company focusing on the development and commercialization ... that new clinical findings including a summary of ... doctors at numerous lectures during the Transcatheter Cardiovascular ...
... SILVER SPRING, Md., Nov. 8, 2011 Many ... their medical conditions at home.  These conditions include ... disorders, migraines and cancer. Sharps are also used ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO )   ...
Cached Medicine Technology:InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 2InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 3InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 4FDA CONSUMER HEALTH INFORMATION - Improperly Discarded 'Sharps' Can Be Dangerous 2
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... it comes to pain, the two competing schools of thought ... in your body". A new study led by University of ... the two. Depression and pain often co-occur, but ... To examine the interaction between depression and pain, Dr. Chantal ...
... The prevalence of mild sleep-disordered breathing in young ... will be presented Monday, June 7, 2010, in San ... of the Associated Professional Sleep Societies LLC. Results ... mild sleep-disordered breathing in elementary-school children increased steadily from ...
... CITYFindings of a clinical trial reported at SNM,s 57th ... could improve diagnosis of recurrent prostate cancer and determine ... "Despite definitive treatment, about 30 percent of ... the division of nuclear medicine and molecular imaging and ...
... SALT LAKE CITYChester A. Mathis, Ph.D., director of the ... University of Pittsburgh, has been named as this year,s ... was presented the award by SNMa leading molecular imaging ... 5𔃇, in Salt Lake City, Utah. The Paul C. ...
... treatment for melanoma that has spread to the liver ... liver,s blood vessels, according to a study sponsored by ... led by James F. Pingpank, M.D., associate professor of ... oncologist with UPMC Cancer Centers. The results will be ...
... leukemia patients responded to Sprycel and Tasigna than Gleevec ... drugs, dasatinib (Sprycel) and nilotinib (Tasigna), appear better than ... myeloid leukemia and should be considered as first-line treatments, ... change clinical practice, are to be presented Saturday at ...
Cached Medicine News:Health News:Study finds a seasonal variance in sleep-disordered breathing in young children 2Health News:Molecular imaging detects recurrent prostate cancer 2Health News:Chester A. Mathis receives SNM's 2010 Aebersold Award 2Health News:Chester A. Mathis receives SNM's 2010 Aebersold Award 3Health News:New treatment method safe, effective for advanced melanoma patients 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 3Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 4
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
... OS) makes the patient appointment, the charge ... the MedPlexus System accessible through a ... have access to data that was previously ... appointment schedules, create super bills and more. ...
MD Coder Charge Capture Pocket PC Edition is a charge capture tool. We have integrated the feedback from hospitals and physicians. MD Coder Charge Capture supports both the Palm OS and Pocket PC plat...
... Zapcode follows the HCFA Evaluation and Management ... the history and exam information, it calculates the ... You can also see the effect of changing ... all of the information you entered to create ...
Medicine Products: